MDRX Stock - Veradigm Inc.
Unlock GoAI Insights for MDRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $588.02M | $577.43M | $1.50B | $1.63B | $1.75B |
| Gross Profit | $308.42M | $258.15M | $565.70M | $574.51M | $724.54M |
| Gross Margin | 52.5% | 44.7% | 37.6% | 35.2% | 41.4% |
| Operating Income | $-27,103,000 | $75.67M | $-57,662,000 | $-99,689,000 | $-95,052,000 |
| Net Income | $-86,462,000 | $134.44M | $700.41M | $-182,178,000 | $363.74M |
| Net Margin | -14.7% | 23.3% | 46.6% | -11.2% | 20.8% |
| EPS | $-0.67 | $1.03 | $4.37 | $-1.10 | $2.07 |
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 19th 2024 | Deutsche Bank | Downgrade | Hold | $10← $15 |
| January 3rd 2024 | Barclays | Initiation | Equal Weight | $11 |
| July 6th 2023 | Argus | Downgrade | Hold | - |
| April 12th 2023 | Stephens | Initiation | Equal Weight | $13 |
| February 1st 2023 | Piper Sandler | Downgrade | Neutral | $18.5← $17 |
| December 7th 2022 | Argus | Upgrade | Buy | $26 |
| November 9th 2022 | Goldman | Upgrade | Buy | $23← $22 |
| November 4th 2022 | Piper Sandler | Resumed | Overweight | $17 |
| September 16th 2022 | KeyBanc Capital Markets | Initiation | Sector Weight | - |
| July 12th 2022 | Goldman | Initiation | Neutral | $21 |
Earnings History & Surprises
MDRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 8, 2025 | $0.07 | $0.07 | 0.0% | = MET |
Q2 2025 | May 9, 2025 | $0.07 | $0.06 | -21.4% | ✗ MISS |
Q1 2025 | Mar 18, 2025 | $0.28 | $0.22 | -21.4% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | — | — | — | — |
Q4 2023 | Dec 28, 2023 | $0.22 | $0.20 | -9.1% | ✗ MISS |
Q3 2023 | Sep 28, 2023 | $0.20 | $0.12 | -40.0% | ✗ MISS |
Q2 2023 | Jun 29, 2023 | $0.18 | $0.09 | -50.0% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $0.27 | $0.72 | +166.7% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.19 | $0.23 | +21.1% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.16 | $0.18 | +12.5% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $0.21 | $0.13 | -38.1% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $0.32 | $0.79 | +146.9% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $0.18 | $0.27 | +50.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $0.18 | $0.23 | +27.8% | ✓ BEAT |
Q2 2021 | Apr 29, 2021 | $0.15 | $0.19 | +26.7% | ✓ BEAT |
Q1 2021 | Feb 25, 2021 | $0.22 | $0.29 | +31.8% | ✓ BEAT |
Q4 2020 | Oct 29, 2020 | $0.18 | $0.20 | +11.1% | ✓ BEAT |
Q3 2020 | Jul 30, 2020 | $0.12 | $0.18 | +50.0% | ✓ BEAT |
Q2 2020 | May 7, 2020 | $0.14 | $0.09 | -35.7% | ✗ MISS |
Q1 2020 | Mar 2, 2020 | $0.18 | $0.17 | -5.6% | ✗ MISS |
Frequently Asked Questions about MDRX
What is MDRX's current stock price?
What is the analyst price target for MDRX?
What sector is Veradigm Inc. in?
What is MDRX's market cap?
Does MDRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MDRX for comparison